|
|||||
|
|
Mycophenolate Mofetil for the Treatment of Multiple Sclerosis-associated Uveitis |
|
| Authors: | Alireza Hedayatfar Khalil Ghasemi Falavarjani Masoud Soheilian Navid Elmi Sadr Mehdi Modarres Mohammad Mehdi Parvaresh |
| Affiliation: | 1. Noor Ophthalmic Research Center, Noor Eye Hospital, Tehran, Iran;2. Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran;3. Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran;4. Ophthalmic Research Center, Labbafinejad Medical Center, Shahid Beheshti Medical University, Tehran, Iran |
| Abstract: | Purpose: To report the efficacy of mycophenolate mofetil (MMF) as adjunctive therapy for the treatment of multiple sclerosis (MS)-associated uveitis. Methods: In this retrospective, interventional case series, patients with MS-associated uveitis who were treated by MMF as an adjunct therapy to systemic corticosteroid were studied. Patients’ demographics, clinical course, response to treatment, and complications were assessed. Results: A total of 30 eyes of 15 patients with a mean age of 34.5 ± 8.3 years were studied. In three patients (20%), onset of uveitis preceded the diagnosis of MS. The course of MS was relapsing–remitting in 11 patients (73.3%) and secondary progressive in four patients (26.7%). At 1 year after institution of MMF, all the patients were on oral prednisolone ≤ 7.5 mg/day, all eyes were quiet without macular edema, and 53.3% of eyes gained visual improvement. Supplemental periocular and intraocular injections were needed during the first 6 months after starting MMF therapy. The systemic adverse effects were transient and minor in severity. Conclusions: MMF had beneficial effects on vision and intraocular inflammation with an acceptable safety profile. |
| Keywords: | Multiple sclerosis mycophenolate mofetil uveitis |